Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.

This research article explores the safety and effectiveness of a synthetic peptide (N15Y) derived from a protein in the bacteria Rhodococcus equi as a protective vaccine against this bacteria in mice and horses. The effectiveness of the vaccine was enhanced when given with an additive (an adjuvant) named IMS3012.

Research methodology

• The study began with the identification of a key protein, VapA, in the cell membrane of the bacteria Rhodococcus equi. A specific segment of this protein (amino acids 65-78) was identified as being highly significant for the immune response, and a synthetic replication of this segment, named N15Y, was created.
• The synthetic peptide N15Y was first tested as a vaccine in mice. The mice were given a single dose of the N15Y peptide vaccine in the presence of an unspecified adjuvant.
• The immune response in the mice was observed by examining the levels of antibodies in the blood (sera) of the mice. The researchers particularly observed delayed clearance of the bacteria in the tissues of the immunized mice compared to control mice.
• The N15Y peptide vaccine was then tested in a larger study on horses. Different adjuvants were tested alongside the peptide to compare their effectiveness: IMS3012, IMS2211, ISA35, and placebo.
• The immune responses in the horses were observed through measuring the levels of different antibodies (IgGb subclass) in their sera. The researchers also monitored how the immune cells of the horses responded to the vaccine by examining levels of immune-related proteins (INF-gamma, IL-2, IL-10 and IL-4) in the horses’ blood lymphocytes.

Research findings

• The use of the N15Y peptide vaccine was found to stimulate the immune system in both mice and horses, generating a immune response against Rhodococcus equi.
• However, in immunized mice, the clearing of the bacteria from their tissues was observed to be slower compared to non-immunized control mice.
• In horses, the N15Y peptide vaccine generated an immune response in all horses except those given the placebo. The strongest response was observed in horses given the adjuvant IMS3012.
• In addition, the horses given IMS3012 displayed increased levels of immune-related proteins and a significant decrease in the levels of IL-4, an immune protein associated with increased inflammation.

Concluding remarks

• The results of the study suggest that the synthetic peptide N15Y, particularly when used in conjunction with the adjuvant IMS3012, may be effective as a vaccine for protection against Rhodococcus equi in horses.
• More research is needed to understand why immunized mice experienced a delay in bacterial clearance, and to test the longer-term effectiveness and safety of the vaccine.